212 related articles for article (PubMed ID: 32948541)
1. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.
Thom H; Jansen J; Shafrin J; Zhao L; Joseph G; Cheng HY; Gupta S; Shah N
BMJ Open; 2020 Sep; 10(9):e034147. PubMed ID: 32948541
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
3. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
[TBL] [Abstract][Full Text] [Related]
7. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
Weaver SB; Rungkitwattanakul D; Singh D
J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
[TBL] [Abstract][Full Text] [Related]
11. Crizanlizumab: First Approval.
Blair HA
Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
[TBL] [Abstract][Full Text] [Related]
12. Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series.
Idowu M; Garcia RL; Sule OB
J Investig Med High Impact Case Rep; 2023; 11():23247096231191873. PubMed ID: 37731262
[TBL] [Abstract][Full Text] [Related]
13. Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
Desai PC; Chen CC; McGuiness CB; Yasuda M; Lee S; Paulose J; He J; Yen G
Curr Med Res Opin; 2023 Apr; 39(4):555-565. PubMed ID: 36883332
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of patients with sickle cell disease treated with crizanlizumab.
Chan KH; Buddharaju R; Idowu M
J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007
[TBL] [Abstract][Full Text] [Related]
15. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS
Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
Sy SKB; Tanaka C; Grosch K
Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
[TBL] [Abstract][Full Text] [Related]
17. Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease.
Gardner RV
Drugs Today (Barc); 2020 Nov; 56(11):705-714. PubMed ID: 33332478
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
Migotsky M; Beestrum M; Badawy SM
Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
[TBL] [Abstract][Full Text] [Related]
19. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
Stevens DL; Hix M; Gildon BL
J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
[No Abstract] [Full Text] [Related]
20. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
